7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Tooth Ankylosis D020254 1 associated lipids
Spondylarthropathies D025242 1 associated lipids
Emphysema D004646 1 associated lipids
Arteriolosclerosis D050379 1 associated lipids
Alphavirus Infections D018354 1 associated lipids
Ankylosis D000844 1 associated lipids
Jaw, Edentulous D007575 1 associated lipids
Chondrocalcinosis D002805 1 associated lipids
Lymphangioleiomyomatosis D018192 1 associated lipids
Carcinoid Heart Disease D002275 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Younes A and Aggarwall BB Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. 2003 Cancer pmid:12879461
Nawroth P et al. [Osteoporosis and cardiovascular disease--two sides of the same coin?]. 2003 Med. Klin. (Munich) pmid:12928809
Padigel UM et al. TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. 2003 J. Immunol. pmid:14607948
Terpos E et al. New insights into the pathophysiology and management of bone disease in multiple myeloma. 2003 Br. J. Haematol. pmid:14632767
Ha H et al. Lipid rafts are important for the association of RANK and TRAF6. 2003 Exp. Mol. Med. pmid:14508068
Zhang L et al. The role of calmodulin in the regulation of osteoclastogenesis. 2003 Endocrinology pmid:12960067
Abrahamsen B et al. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. 2003 Calcif. Tissue Int. pmid:12384814
Chan BY et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. 2003 Clin. Chem. pmid:14633883
Jung K et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. 2003 J. Urol. pmid:14634401
Ha H et al. Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. 2003 J. Biol. Chem. pmid:12637570
Ritchlin CT et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 2003 J. Clin. Invest. pmid:12639988
Al-Qawasmi RA et al. Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. 2003 J. Dent. Res. pmid:12709501
Fujita D et al. Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12711253
Katavić V et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. 2003 J. Immunol. pmid:12538719
Nishimura K et al. Effects of irradiation on cementum matrix cytokins function during periodontal regeneration. 2003 Hum. Cell pmid:15147042
Choi BK et al. Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. 2003 Infect. Immun. pmid:12496170
Liu D et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. 2003 Int. J. Mol. Med. pmid:12469211
Crotti TN et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. 2003 J. Rheumatol. pmid:14677171
Helfrich MH Osteoclast diseases. 2003 Microsc. Res. Tech. pmid:12879419
Walsh MC and Choi Y Biology of the TRANCE axis. 2003 Jun-Aug Cytokine Growth Factor Rev. pmid:12787563
Smith BB et al. A toxicity profile of osteoprotegerin in the cynomolgus monkey. 2003 Sep-Oct Int. J. Toxicol. pmid:14555415
Ogasawara T et al. In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue. 2004 J. Periodont. Res. pmid:14687227
Blair HC and Athanasou NA Recent advances in osteoclast biology and pathological bone resorption. 2004 Histol. Histopathol. pmid:14702187
Kumamoto H and Ooya K Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. 2004 J. Oral Pathol. Med. pmid:14675140
Crisafulli A et al. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. 2004 J. Clin. Endocrinol. Metab. pmid:14715848
Onyia JE et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. 2004 J. Pharmacol. Exp. Ther. pmid:14718597
Smith MD Comment on review on T cells in bone biology. 2004 Rheumatology (Oxford) pmid:15448222
Boabaid F et al. Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. 2004 J. Periodontol. pmid:15455742
Schett G et al. Soluble RANKL and risk of nontraumatic fracture. 2004 JAMA pmid:14996780
Tsuji K et al. Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. 2004 J. Bone Miner. Metab. pmid:14999519
Jørgensen HL et al. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. 2004 J. Bone Miner. Metab. pmid:14999524
Kobayashi-Sakamoto M et al. NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. 2004 Biochem. Biophys. Res. Commun. pmid:15013432
MacQuarrie RA et al. Wear-particle-induced osteoclast osteolysis: the role of particulates and mechanical strain. 2004 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:15015218
Ishii T et al. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. 2004 Biochem. Biophys. Res. Commun. pmid:15033472
Suda T and Miyaura C [Recent advance in basic research for osteoporosis]. 2004 Nippon Rinsho pmid:15035090
Matsumoto T [Recent advances in the regulation of bone remodeling]. 2004 Nippon Rinsho pmid:15035093
Okumura S et al. [Regulatory mechanism of osteoclast differentiation and function]. 2004 Nippon Rinsho pmid:15035103
Udagawa N et al. [Possible role of RANKL in bone resorption]. 2004 Nippon Rinsho pmid:15035104
Inoue D [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. 2004 Nippon Rinsho pmid:15035105
Suzuki Y [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. 2004 Nippon Rinsho pmid:15035106
Miyaura C [LPS]. 2004 Nippon Rinsho pmid:15035108
Sattler AM et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. 2004 Calcif. Tissue Int. pmid:14523602
Bergh JJ et al. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. 2004 Endocrinology pmid:14525906
Wise GE et al. Regulation of secretion of osteoprotegerin in rat dental follicle cells. 2004 Eur. J. Oral Sci. pmid:15458504
Dai SM et al. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. 2004 Ann. Rheum. Dis. pmid:15479886
Wang JC et al. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). 2004 Exp. Hematol. pmid:15504545
Fan X et al. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. 2004 Endocrinology pmid:14563699
Kondo T et al. 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. 2004 J. Bone Miner. Res. pmid:15312241
Daroszewska A et al. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. 2004 J. Bone Miner. Res. pmid:15312251
Liu JM et al. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. 2004 Zhonghua Nei Ke Za Zhi pmid:15312444
Jacobson A et al. Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. 2004 Biochem. Biophys. Res. Commun. pmid:15313187
Ishida M and Amano S Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. 2004 J. Bone Miner. Metab. pmid:15316862
Sato T et al. Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. 2004 Am. J. Hematol. pmid:15307108
Giuliani N et al. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). 2004 Exp. Hematol. pmid:15308315
Colucci S et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. 2004 Blood pmid:15308561
Miyazaki T et al. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. 2004 J. Cell. Biochem. pmid:15372622
Jeffcoate W Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? 2004 Diabetologia pmid:15322748
Liu Z et al. Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. 2004 Protein Pept. Lett. pmid:15327363
Politou M et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). 2004 Br. J. Haematol. pmid:15327520
Xiao XH et al. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. 2004 Zhonghua Yi Xue Za Zhi pmid:15730627
Tiranathanagul S et al. Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. 2004 J. Periodontol. pmid:15732867
Bord S et al. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. 2004 Br. J. Haematol. pmid:15238146
Buxton EC et al. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). 2004 J. Clin. Endocrinol. Metab. pmid:15240611
Kochanowska I et al. Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle. 2004 Cell Tissue Bank pmid:15241009
Corso A et al. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. 2004 Leukemia pmid:15241438
Harada M et al. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. 2004 Hum. Reprod. pmid:15242994
Kang HS et al. Receptor activator of nuclear factor-kappaB is induced by a rottlerin-sensitive and p38 MAP kinase-dependent pathway during monocyte differentiation. 2004 Mol. Cells pmid:15232218
Kazama JJ Osteoprotegerin and bone mineral metabolism in renal failure. 2004 Curr. Opin. Nephrol. Hypertens. pmid:15199291
Walsh NC and Gravallese EM Bone loss in inflammatory arthritis: mechanisms and treatment strategies. 2004 Curr Opin Rheumatol pmid:15201606
Terpos E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. 2004 Leukemia pmid:15215875
Brändström H et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). 2004 Blood Press. pmid:15223723
Wilson SE et al. RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. 2004 Invest. Ophthalmol. Vis. Sci. pmid:15223796
Pioletti DP and Kottelat A The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. 2004 Biomaterials pmid:15172492
Livshits G et al. Genetic influences on the circulating cytokines involved in osteoclastogenesis. 2004 J. Med. Genet. pmid:15173242
Ueland T et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. 2004 J. Am. Coll. Cardiol. pmid:15542278
Demer LL and Abedin M Skeleton key to vascular disease. 2004 J. Am. Coll. Cardiol. pmid:15542279
Vidal K et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. 2004 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:15521102
Lee CK et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. 2004 Arthritis Rheum. pmid:15593184
Grzegorzewska AE and MÅ‚ot M Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. 2004 Rocz. Akad. Med. Bialymst. pmid:15631341
Grzegorzewska AE and MÅ‚ot M Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. 2004 Rocz. Akad. Med. Bialymst. pmid:15631342
Yeung RS The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. 2004 J. Rheumatol. pmid:15124240
Masi L et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? 2004 J. Rheumatol. pmid:15124262
Eaton CL et al. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. 2004 Prostate pmid:15042606
Nitta K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. 2004 Nephrol. Dial. Transplant. pmid:15128884
O' Gradaigh D et al. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. 2004 Ann. Rheum. Dis. pmid:15020327
Milstead JR et al. Spaceflight and hindlimb suspension disuse models in mice. 2004 Biomed Sci Instrum pmid:15133943
Karst M et al. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. 2004 J. Cell. Physiol. pmid:15137062
Emanuele E et al. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. 2004 Int. J. Mol. Med. pmid:15138623
Kyrtsonis MC et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. 2004 Eur. J. Haematol. pmid:15089762
Miao D et al. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. 2004 Endocrinology pmid:15090463
Haynes DR et al. Regulation of osteoclast activity in peri-implant tissues. 2004 Biomaterials pmid:15109848
Ito S and Hata T Crystal structure of RANK ligand involved in bone metabolism. 2004 Vitam. Horm. pmid:15110169
Hao C et al. Modulation of TRAIL signaling complex. 2004 Vitam. Horm. pmid:15110173
Herrmann M and Herrmann W The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. 2004 Clin. Chem. Lab. Med. pmid:15576300
Jono S [Risk factors of atherosclerosis in end-stage renal disease patients]. 2004 Clin Calcium pmid:15576949
Shimizu M and Tamura T [Regulation of bone mineralization by parathyroid hormone]. 2004 Clin Calcium pmid:15577058
Ogata H et al. [Prophylaxis and treatment of adynamic bone]. 2004 Clin Calcium pmid:15577107
Altun A et al. Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. 2004 J. Endocrinol. Invest. pmid:15648548
Buzi F et al. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. 2004 Clin. Endocrinol. (Oxf) pmid:14678293
Cheng X et al. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. 2004 J. Biol. Chem. pmid:14679212

Table of Content